|
受注:045-509-1970 |
技術サポート:tech@selleck.co.jp 平日9:00〜18:00 1営業日以内にご連絡を差し上げます |
|
Synonyms | N/A | Storage (From the date of receipt) |
3 years -20°C powder 1 years -80°C in solvent |
|||
| 化学式 | C22H12Cl4N2O4 |
||||||
| 分子量 | 510.15 | CAS No. | 1227962-62-0 | ||||
| Solubility (25°C)* | 体外 | DMSO | 100 mg/mL (196.02 mM) | ||||
| Ethanol | 59 mg/mL (115.65 mM) | ||||||
| Water | Insoluble | ||||||
| 体内 (毎回新しく調製した物を用意してください) |
|
||||||
|
* <1 mg/ml means slightly soluble or insoluble. * Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations. |
|||||||
| 製品説明 | Marinopyrrole A (Maritoclax) is a selective Mcl-1 antagonist. It binds to Mcl-1, but not Bcl-XL, and targets Mcl-1 for proteasomal degradation. Maritoclax disrupts the interaction between Bim and Mcl-1 with an IC50 of 10.1 μM. |
|---|---|
| in vitro | Marinopyrrole A (Maritoclax) induces Mcl-1 degradation via the proteasome system, which is associated with its pro-apoptotic activity. It selectively kills Mcl-1-dependent, but not Bcl-2- or Bcl-XL-dependent, leukemia cells and markedly enhances the efficacy of ABT-737 against hematologic malignancies, including K562, Raji, and multidrug-resistant HL60/VCR, by ∼60- to 2000-fold at 1-2 μM. This compound blocks the interaction between a biotin-labeled Bim-BH3 peptide and GST-Mcl-1 in a dose-dependent manner with an IC50 value of 10.1 μM, while it does not inhibit the binding of Bim-BH3 peptide to GST-Bcl-XL at concentrations up to 80 μM. It induces caspase-3 activation by degradation of Mcl-1 protein. Treatment with maritoclax markedly reduces the half-life of Mcl-1 to ∼0.5 h as compared with nearly 3 h in control cells. It has no apparent effect on Mcl-1 (Ser159/Thr163) phosphorylation, suggesting that it induces phosphorylation-independent Mcl-1 degradation[1]. Marinopyrrole A has potent concentration-dependent bactericidal activity against clinically relevant hospital- and community-acquired MRSA strains. It shows limited toxicity to mammalian cell lines (at >20× MIC)[2]. Maritoclax sensitivity is cell type specific. It is not effective in HeLa, HEK293, or MEF cells. This compound is not a substrate for p-gp mediated drug efflux[3]. |
| in vivo | When administered intraperitoneally at 20 mg/kg/d, Marinopyrrole A (Maritoclax) causes significant U937 tumor shrinkage, as well as a 36% tumor remission rate in athymic nude mice, without apparent toxicity to healthy tissue or circulating blood cells[3]. |
| 細胞アッセイ | 細胞株 | K562 cells |
|---|---|---|
| 濃度 | 2 μM | |
| 反応時間 | 12 h | |
| 実験の流れ | K562 cells expressing Mcl-1-IRES-BimEL are treated with DMSO, 2 μM Marinopyrrole A (Maritoclax) alone, or in combination with 1 μM MG132 for 12 h. Cells are lysed in 1% Chaps buffer (1% Chaps, 150 mM NaCl, 10 mM Hepes, pH7.4) containing protease inhibitors. Cell lysates containing 350 μg of protein are incubated with 4 μl of rabbit anti-Mcl-1 antiserum or control pre-immune serum in 250 μl of the same lysis buffer at 4 °C overnight on a rotator. Immunoprecipitates are collected by adding 20 μl of protein A-Sepharose beads for 3 h at 4 °C, followed by centrifugation at 6,000 rpm for 30 s. The beads are washed five times with the same lysis buffer, boiled for 5 min in Laemmli sample buffer and analyzed by Western blotting. |
|
| 動物実験 | 動物モデル | Female athymic nude (NCI Athymic NCr-nu/nu 01B74) mice |
| 投薬量 | 20 mg/kg | |
| 投与方法 | i.p. |
|
| Mechanisms of MCL-1 Protein Stability Induced by MCL-1 Antagonists in B-Cell Malignancies [ Clin Cancer Res, 2023, 29(2):446-457] | PubMed: 36346691 |
| Mechanisms of MCL-1 Protein Stability Induced by MCL-1 Antagonists in B-Cell Malignancies [ Clin Cancer Res, 2023, 29(2):446-457] | PubMed: 36346691 |
| PHLPP1 deficiency ameliorates cardiomyocyte death and cardiac dysfunction through inhibiting Mcl-1 degradation [ Cell Signal, 2022, S0898-6568(22)00041-9] | PubMed: 35151832 |
| The ribosomal RPL10 R98S mutation drives IRES-dependent BCL-2 translation in T-ALL [Kampen KR, et al. Leukemia, 2019, 33(2):319-332] | PubMed: 29930300 |
| Maritoclax Enhances TRAIL-Induced Apoptosis via CHOP-Mediated Upregulation of DR5 and miR-708-Mediated Downregulation of cFLIP [ Molecules, 2018, 23(11)E3030] | PubMed: 30463333 |
長期の保管のために-20°Cの下で製品を保ってください。
人間や獣医の診断であるか治療的な使用のためにでない。
各々の製品のための特定の保管と取扱い情報は、製品データシートの上で示されます。大部分のSelleck製品は、推薦された状況の下で安定です。製品は、推薦された保管温度と異なる温度で、時々出荷されます。長期の保管のために必要とされてそれと異なる温度で、多くの製品は、短期もので安定です。品質を維持するが、夜通しの積荷のために最も経済的な貯蔵状況を用いてあなたの送料を保存する状況の下に、製品が出荷されることを、我々は確実とします。製品の受領と同時に、製品データシートの上で貯蔵推薦に従ってください。